Xeris Pharmaceuticals Inc. [NASDAQ: XERS] traded at a low on 07/07/21, posting a -1.78 loss after which it closed the day’ session at $3.87. The company report on July 3, 2021 that Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, announced that on July 1, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 80,250 shares of its common stock to 37 new employee(s) under Xeris’ Inducement Equity Plan.
Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual’s entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The non-qualified stock options will vest over a period of four years, either 25% on the first anniversary of the grant with the remaining 75% vesting in thirty-six equal monthly installments thereafter, or 36% on 18 months after the grant date with the remaining 64% vesting in ten equal quarterly installments thereafter and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. The restricted stock units will vest over a period of four years in equal annual installments and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.
The results of the trading session contributed to over 1775386 shares changing hands. Over the past one week, the price volatility of Xeris Pharmaceuticals Inc. stands at 6.60% while the volatility over the past one month is 7.40%.
The market cap for XERS stock reached $251.98 million, with 61.24 million shares outstanding and 55.36 million shares in the current float. Compared to the average trading volume of 3.09M shares, XERS reached a trading volume of 1775386 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Xeris Pharmaceuticals Inc. [XERS]?
RBC Capital Mkts have made an estimate for Xeris Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 07, 2021. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on February 18, 2020, representing the official price target for Xeris Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $24, while RBC Capital Mkts analysts kept a Outperform rating on XERS stock.
The Average True Range (ATR) for Xeris Pharmaceuticals Inc. is set at 0.32, with the Price to Sales ratio for XERS stock in the period of the last 12 months amounting to 9.40. The Price to Book ratio for the last quarter was 5.37, with the Price to Cash per share for the same quarter was set at 2.09.
How has XERS stock performed recently?
Xeris Pharmaceuticals Inc. [XERS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.83. With this latest performance, XERS shares gained by 3.20% in over the last four-week period, additionally sinking by -25.15% over the last 6 months – not to mention a rise of 48.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XERS stock in for the last two-week period is set at 46.77, with the RSI for the last a single of trading hit 42.52, and the three-weeks RSI is set at 48.27 for Xeris Pharmaceuticals Inc. [XERS]. The present Moving Average for the last 50 days of trading for this stock 3.75, while it was recorded at 4.06 for the last single week of trading, and 4.77 for the last 200 days.
Xeris Pharmaceuticals Inc. [XERS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Xeris Pharmaceuticals Inc. [XERS] shares currently have an operating margin of -400.52 and a Gross Margin at +54.84. Xeris Pharmaceuticals Inc.’s Net Margin is presently recorded at -446.00.
Return on Total Capital for XERS is now -84.59, given the latest momentum, and Return on Invested Capital for the company is -94.19. Return on Equity for this stock declined to -378.20, with Return on Assets sitting at -67.98. When it comes to the capital structure of this company, Xeris Pharmaceuticals Inc. [XERS] has a Total Debt to Total Equity ratio set at 257.76. Additionally, XERS Total Debt to Total Capital is recorded at 72.05, with Total Debt to Total Assets ending up at 54.68. Long-Term Debt to Equity for the company is recorded at 257.76, with the Long-Term Debt to Total Capital now at 72.05.
Reflecting on the efficiency of the workforce at the company, Xeris Pharmaceuticals Inc. [XERS] managed to generate an average of -$506,333 per employee. Receivables Turnover for the company is 3.27 with a Total Asset Turnover recorded at a value of 0.15.Xeris Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.90.
Insider trade positions for Xeris Pharmaceuticals Inc. [XERS]
There are presently around $128 million, or 52.40% of XERS stock, in the hands of institutional investors. The top three institutional holders of XERS stocks are: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 6,553,398, which is approximately New of the company’s market cap and around 2.90% of the total institutional ownership; BLACKROCK INC., holding 3,764,948 shares of the stock with an approximate value of $14.57 million in XERS stocks shares; and SESSA CAPITAL IM, L.P., currently with $13.23 million in XERS stock with ownership of nearly -18.077% of the company’s market capitalization.
Positions in Xeris Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 58 institutional holders increased their position in Xeris Pharmaceuticals Inc. [NASDAQ:XERS] by around 10,341,831 shares. Additionally, 38 investors decreased positions by around 2,798,429 shares, while 20 investors held positions by with 20,051,571 shares. The mentioned changes placed institutional holdings at 33,191,831 shares, according to the latest SEC report filing. XERS stock had 19 new institutional investments in for a total of 7,495,670 shares, while 13 institutional investors sold positions of 694,642 shares during the same period.